|
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) Clinical research trials and Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup). Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)  Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
For Condition: Ischemic Optic Neuropathy
Status: No longer recruiting
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: To follow all patients enrolled in the original Ischemic Optic Neuropathy Decompression Trial (IONDT) to determine (1) the incidence of non-arteritic ischemic optic neuropathy (NAION) in the second eye, (2) changes in visual acuity over time in both the study and second eye, and (3) other aspects of the natural history of NAION.
Details: NAION is the most common cause of acute optic nerve disease in the elderly, causing permanent and severe visual loss. No proven treatment currently exists to reverse or arrest this loss. There is no accepted method for the prevention or reduction of the likelihood of second eye involvement. NAION strikes both eyes in as many as 40 percent of affected patients (Beri et al. 1987), with a 2-year risk of about 25 percent (Steven Feldon, personal communication to SEK). IONDT compared optic nerve decompression surgery (ONDS), which was becoming a widely used treatment for NAION, with careful followup alone, in patients with newly diagnosed NAION. The rationale for the surgery was that NAION was caused by impaired blood flow to the optic nerve and that decompression surgery would restore vision by alleviating pressure surrounding the nerve. Because ONDS was fast becoming the standard of care, evaluation of the safety and efficacy of the procedure was tested in the context of a randomized clinical trial. Within 2 years of the start of the IONDT, the Data and Safety Monitoring Committee recommended cessation of the clinical trial recruitment. The National Institutes of Health issued a clinical alert to 25,000 ophthalmologists and neurologists describing the study findings that surgery was no better than careful followup and may be harmful (IONDT 1995). It was recommended that ONDS not be used in cases of NAION. Thus, the IONDT findings not only have led to a costly and ineffective surgery to be abandoned as a treatment for NAION, but also have left practitioners with a dearth of treatment choices. The IONDT is the first multicenter, prospective study of newly diagnosed patients with NAION. The baseline history and examination, which took place within 14 days of the onset of symptoms, used standardized methods and diagnostic criteria to collect data on all factors possibly relating to the etiology of NAION. In reports from previous studies that present data on both initial and final visual acuities, no data are available regarding change in visual acuity over time for individual patients. Where data are available on final visual acuity, reported rates of improvement are low, ranging from 0 percent to 33 percent for untreated eyes. The IONDT found, however, an improvement of three or more lines in 42.7 percent of patients who received careful followup. NAION in both eyes has been reported in as few as 10.5 percent and as many as 73 percent of patients. In a study of bilateral NAION where all patients were prospectively logged, Beri et al. reported that 17.5 percent of patients developed bilateral disease at 1 year of followup and 34.5 percent developed it at 5 years. However, Beck et al., using a life table analysis on the same cohort reported by Beri et al., estimated the risk of bilateral NAION to be 12 percent within 2 years and 19 percent within 5 years. The IONDT has so far similarly reported a 12 percent (25/216) incidence of bilateral NAION in its randomized patients. The incidence in the nonrandomized group, 91 percent of whom had visual acuity better than 20/64, is much lower at 4 percent (5/136). Thus, continued followup of the IONDT cohort is critically important to ascertain a clear picture of the natural history of NAION in terms of involvement of the second eye and long-term vision. Data obtained will be critical in understanding the etiology of the disease and in generating hypotheses for testing further treatments for the disease. The IONDT Followup Study will continue to monitor vision and other health outcomes in patients originally enrolled in the IONDT, whether randomized to one of the two treatment groups or whether followed as part of the natural history cohort. All IONDT patients were diagnosed with NAION within 14 days of onset of symptoms, have had a minimum of 2 years of continuous followup, and will be followed for an additional 4 years in the Followup Study. Patients will have annual visits at the original IONDT Clinical Center or, if necessary, with a surrogate provider. If NAION occurs in the second eye, the patient will be asked to visit the clinic for a special visit. The Coordinating Center will telephone the patients on a quarterly basis, between annual visits. Outcomes that will be examined include: - incidence of NAION in the second eye, - medical or ocular events surrounding the occurrence of NAION, - visual acuity (measured using the New York Lighthouse charts). In the event of an NAION event in the second eye, the patient's visual field will be tested by using the Humphrey Perimeter.
Eligibility:
Study Type: Observational, Longitudinal
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: All living patients from the 420 patients originally enrolled in the IONDT have been asked to participate in the IONDT Followup Study. No new patients are being recruited.
Total Enrollment:
Location and Contact Information:
University of Texas
Houston, Texas,
United States
Doheny Eye Institute, University of Southern California
Los Angeles, California,
United States
Emory Eye Center, Emory University
Atlanta, Georgia,
United States
Jules Stein Eye Institute
Los Angeles, California,
United States
Mason Institute of Ophthalmology, University of Missouri - Columbia
Columbia, Missouri,
United States
University of Utah, Department of Ophthalmology
Salt Lake City, Utah,
United States
SUNY Health Science Center, Department of Neurology
Syracuse, New York,
United States
Medical College of Virginia, Department of Neurology
Richmond, Virginia,
United States
William Beaumont Eye Institute, William Beaumont Hospital
Royal Oak, Michigan,
United States
Department of Ophthalmology, University of California, San Francisco
San Francisco, California,
United States
Mayo Clinic
Rochester, Minnesota,
United States
University of Virginia, Department of Ophthalmology
Charlottesville, Virginia,
United States
The Cleveland Clinic Foundation
Cleveland, Ohio,
United States
Department of Ophthalmology, University of Kentucky
Lexington, Kentucky,
United States
Department of Ophthalmology, Michigan State University
East Lansing, Michigan,
United States
Allegheny General Hospital
Pittsburgh, Pennsylvania,
United States
University of South Carolina, Department of Ophthalmology
Columbia, South Carolina,
United States
W.K. Kellogg Eye Center, University of Michigan
Ann Arbor, Michigan,
United States
Carolinas Medical Center
Charlotte, North Carolina,
United States
St. Louis University, Anheuser-Busch Eye Institute
St. Louis, Missouri,
United States
University of Maryland
Baltimore, Maryland,
United States
West Virginia University, Department of Neurology
Morgantown, West Virginia,
United States
Department of Ophthalmology, University of Florida
Gainesville, Florida,
United States
Department of Ophthalmology, University of Illinois
Chicago, Illinois,
United States
Additional Information:
Study ID Numbers: NEI-25;
Study Start Date: October 1994
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000126
Other Ischemic Optic Neuropathy Studies:
1. Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
Related Studies:
Other Ischemic Optic Neuropathy Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
|
|
|
|
|
|
|
|
